All patients
Age < 65y (younger) Age > 65y Asian type ECOG ⩾ 1 ECOG 0 hemoglobin concentration > 10g/dl PD-L1 < 1% PD-L1 > 1%
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/advanced OC (mOC) - 2nd line (L2), avelumab plus pegylated liposomal doxorubicin vs. non platinum-based chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.89 [0.69; 1.15]
0.89 [0.69 ; 1.15 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 378 NA not evaluable progression or deaths (PFS)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.78 [0.54; 1.13]
0.78 [0.54 ; 1.13 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 378 NA not evaluable DCRdetailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2.79 [1.83; 4.24]
2.79 [1.83 ; 4.24 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 378 NA not evaluable objective responses (ORR)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 3.46 [1.39; 8.64]
3.46 [1.39 ; 8.64 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 378 NA not evaluable TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1.66 [1.08; 2.57]
1.66 [1.08 ; 2.57 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable TRAE leading to death (grade 5)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.48 [0.02; 14.54]
0.48 [0.02 ; 14.54 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable TRAE leading to discontinuation (any grade)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.58 [0.23; 1.44]
0.58 [0.23 ; 1.44 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Abdominal pain TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.06; 15.67]
0.97 [0.06 ; 15.67 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.02; 49.28]
0.97 [0.02 ; 49.28 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1.95 [0.07; 58.51]
1.95 [0.07 ; 58.51 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Anaemia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.64 [0.22; 1.83]
0.64 [0.22 ; 1.83 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Asthenia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 3.96 [0.44; 35.74]
3.96 [0.44 ; 35.74 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.02; 49.28]
0.97 [0.02 ; 49.28 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Colitis TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1.95 [0.07; 58.51]
1.95 [0.07 ; 58.51 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Constipation TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.02; 49.28]
0.97 [0.02 ; 49.28 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1.95 [0.07; 58.51]
1.95 [0.07 ; 58.51 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1.95 [0.07; 58.51]
1.95 [0.07 ; 58.51 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Dry skin TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.48 [0.02; 14.54]
0.48 [0.02 ; 14.54 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.02; 49.28]
0.97 [0.02 ; 49.28 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Fatigue TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 3.37 [0.91; 12.46]
3.37 [0.91 ; 12.46 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.32 [0.03; 3.11]
0.32 [0.03 ; 3.11 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.02; 49.28]
0.97 [0.02 ; 49.28 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Hypersensitivity TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1.95 [0.07; 58.51]
1.95 [0.07 ; 58.51 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Hypertension TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1.95 [0.07; 58.51]
1.95 [0.07 ; 58.51 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.02; 49.28]
0.97 [0.02 ; 49.28 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Increase AST TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.02; 49.28]
0.97 [0.02 ; 49.28 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 3.92 [0.18; 87.59]
3.92 [0.18 ; 87.59 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 3.92 [0.18; 87.59]
3.92 [0.18 ; 87.59 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.06; 15.67]
0.97 [0.06 ; 15.67 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.32 [0.03; 3.11]
0.32 [0.03 ; 3.11 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 4.97 [0.57; 42.99]
4.97 [0.57 ; 42.99 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.19; 4.88]
0.97 [0.19 ; 4.88 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Nausea TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2.95 [0.30; 28.63]
2.95 [0.30 ; 28.63 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.38; 2.51]
0.97 [0.38 ; 2.51 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2.05 [0.89; 4.69]
2.05 [0.89 ; 4.69 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Pancytopenia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.24 [0.01; 5.38]
0.24 [0.01 ; 5.38 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1.95 [0.07; 58.51]
1.95 [0.07 ; 58.51 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Peripheral oedema TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1.95 [0.07; 58.51]
1.95 [0.07 ; 58.51 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Pneumonia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1.95 [0.07; 58.51]
1.95 [0.07 ; 58.51 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.48 [0.02; 14.54]
0.48 [0.02 ; 14.54 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Pruritic rash TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1.95 [0.07; 58.51]
1.95 [0.07 ; 58.51 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Pruritus TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.02; 49.28]
0.97 [0.02 ; 49.28 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.02; 49.28]
0.97 [0.02 ; 49.28 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Rash TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 3.73 [1.02; 13.61]
3.73 [1.02 ; 13.61 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Sepsis TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.02; 49.28]
0.97 [0.02 ; 49.28 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Skin exfoliation TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1.95 [0.07; 58.51]
1.95 [0.07 ; 58.51 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2.00 [0.67; 5.97]
2.00 [0.67 ; 5.97 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.48 [0.02; 14.54]
0.48 [0.02 ; 14.54 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable Vomiting TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.32 [0.03; 3.11]
0.32 [0.03 ; 3.11 ] JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1 0% 359 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-09 19:52 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 251
- treatments: 1051